Digital Therapeutics and Their Impact on Healthcare

2019-06-10
Price :
Published : Jun-2019
No. of Pages : 130
Table of Contents
1. Preface
1.1 Abbreviations
1.2 Related Reports
1.3 Upcoming Related Reports
2. Executive Summary
2.1 Key Findings
2.2 KOL and Payer Insights
3. Overview - Digital Therapeutics (DTx)
3.1 Digital Therapeutics Definition
3.2 Digital Medicine Definition
3.3 Key Criteria of Digital Therapeutics
3.4 Positioning DTx Within Digital Health
4. DTx Technologies
4.1 Use of Digital Therapeutics
4.2 Types of Digital Therapeutics
4.3 DTx in Clinical Trials
4.4 KOL Perspectives
5. DTx Marketed Products
5.1 Leading Marketed Products
5.2 Key Marketed Products
5.3 Marketed DTx by Device Type
5.4 Marketed DTx by Indication
6. DTx Pipeline Products
6.1 Leading Pipeline Products
6.2 Key Pipeline Products
6.3 Clinical Trial Mapping
6.4 Pipeline DTx by Device Type
6.5 Pipeline DTx by Indication
7. Digital Medicine
7.1 Overview
7.2 Marketed Digital Medicine
7.3 Proteus Discover Products
7.4 Clinical Trial Mapping
7.5 Pipeline Digital Medicine
8. DTx Impact on Healthcare
8.1 Overview
8.2 Role of DTx and Digital Medicine in Clinical Unmet Needs
8.3 KOL Perspectives
8.4 Patient Perspective
8.5 Provider Perspective
8.6 Payer Perspective
8.7 Health System
8.8 What Do Physicians Think?
9. Trends in Digital Therapeutics
9.1 Overview
9.2 Clinical Trial Design
9.3 Regulatory Approvals
9.4 Opportunities for Pharma Companies
9.5 Deals Landscape
9.6 KOLs Perspectives
9.7 Case Studies
10. Market Opportunities
10.1 Overview
10.2 Market Drivers
10.3 Market Barriers
10.4 What Do Physicians Think?
11. DTx Market Access
11.1 Regulatory and Approval in US and EU
11.2 Regulatory and Approval in Japan and China
11.3 Developing a Market Access Strategy for DTx
11.4 What Do Payers Think?
11.5 DTx Regulation in US
11.6 DTx Reimbursement in US
11.6.1 What Do US Payers Think?
11.7 DTx Regulation in UK
11.8 DTx Reimbursement in UK
11.8.1 What Do UK Payers Think?
12. Market Outlook
12.1 Recommendations
12.2 Future Directions for DTx
13. Appendix
13.1 Sources
13.3 Methodology
13.4 Primary Research
13.5 About the Authors
13.6 About GlobalData
13.7 Contact Us
Filed in: Pharmaceutical
Publisher : GlobalData